Provided by the Meniscus Educational Institute |
|
A lunch symposium to be held at
the 34th Annual Congress of the Oncology Nursing Society
San Antonio Marriott Rivercenter
Grand Ballroom C,D, and E
101 Bowie Street
San Antonio, TX 78205
Saturday, May 2, 2009
12:15
PM
to 2:15
PM
|
Supported by an educational grant from Celgene
Corporation. |
 |
|
Agenda and Faculty
11:45–12:15
PM Registration and Lunch
12:15–12:20 PM Welcome and
Introduction
Sandra Kurtin, MS, RN, AOCN, ANP
Hematology/Oncology Nurse Practitioner
Arizona Cancer Center
Tucson, Arizona
12:20–12:55 PM MDS: 2 Case
Presentations and Discussion
• Transfusion-dependent anemia with 5q deletion
• High-risk MDS
Sandra Kurtin, MS, RN, AOCN, ANP
Panel Discussion
12:55–1:30
PM MM: 2 Case
Presentations and Discussion
• Newly diagnosed MM
• Relapsed MM
Beth Faiman, RN, MSN, CNP, AOCN
Nurse Practitioner
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
Panel Discussion
1:30–2:00
PM Summary of
Treatments
Sergio Giralt, MD
Professor of Medicine
Deputy Chair
Department of Stem Cell Transplantation and Cellular Therapy
University of Texas
MD Anderson Cancer Center
2:00–2:10
PM Question-and-Answer
Session
2:10–2:15 PM Wrap-up and
Evaluation
 |
|
Intended Audience
This symposium is intended for nurse practitioners and
nurses who provide care for patients with hematologic
malignancies.
|
|
Rationale and Purpose
Laboratory and clinical
research discoveries are significantly changing the
therapeutic paradigm for patients with hematologic
malignancies, including those with myelodysplastic
syndromes (MDS) and multiple myeloma (MM). Expanding
knowledge of the molecular aberrations that produce
malignant transformation and the complex intracellular
pathways controlling proliferation, progression, and
apoptosis is accelerating the discovery of novel targets
for anticancer therapies. Novel therapies are being
developed at a rapid rate in response to this knowledge,
including multifunctional agents, new applications of
conventional agents, and changes in the role of
hematopoietic stem cell transplantation. Although these
new treatment options offer patients extended survival
and hope for improved quality of life outcomes, their
swift incorporation into standard of care and movement
into community practice pose informational needs and
clinical practice challenges for oncology clinicians.
Oncology nurses are the primary providers of direct
patient care. Therefore, understanding novel mechanisms
of antitumor activity, associated toxicities, and
clinical management strategies for these new therapies
is critical to safe and effective management of patients
receiving them. Many of the emerging therapies may be
administered over extended periods of time, and most
allow patients to be treated in an outpatient setting,
creating unique challenges for health care
professionals. Management of disease- or
treatment-related adverse events is critical to
maintaining therapy and maximizing therapeutic outcomes.
The overall purpose of this activity is to present the
latest developments that will enhance state-of-the-art
medical care for patients with MDS or MM. By using a
case-based tumor board approach, this educational
program will support adherence to evidence-based
practice and guidelines, allowing better integration of
new therapies into clinical practice, with the greatest
impact on improving patient outcomes and enhancing
quality of life in patients with hematologic
malignancies.
|
Learning Objectivess
At the conclusion of this activity, the participant should be better able to
- Describe evolving
trends and standard of practice changes emerging
from recent scientific advances in the management of
MDS and MM, including new and revised classification
systems, risk stratification, and prognostic and
response criteria
- Outline key
treatment-induced complications associated with
newer agents and regimens and related symptom
management approaches designed to maximize patient
safety, quality of life, and adherence to the
therapeutic regimen
- Formulate a plan for
integrating current evidence-based recommendations
into personal clinical practice routines
|
Continuing Education
Statement of Credit—Participants who successfully complete this activity (including completion and submission of the evaluation form) will be issued a statement of credit via e-mail or US mail within 4 weeks.
 Nurses.
This activity for 1.8 contact hours is provided by the Meniscus Educational Institute.
The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. |
 |
Accreditation refers to recognition of educational
activities only and does not imply approval or
endorsement by the Meniscus Educational Institute or the
American Nurses Credentialing Center’s Commission on
Accreditation of any product mentioned.
Provider approved by the California Board of Registered
Nursing, Provider No. 13164, for 1.8 contact hours.
This program has been approved for 1.9 contact hours of
continuing education (which includes 0.8 hours of pharmacology)
by the American Academy of Nurse Practitioners. Program ID 0903140.
This program was planned in accordance with AANP CE Standards and
Policies and AANP Commercial Support Standards.
The Meniscus Educational Institute has been assigned
meeting space to provide an educational program funded
by the Celgene Corporation via an educational grant
during the Oncology Nursing Society’s (ONS) 34th Annual
Congress. The Oncology Nursing Society’s assignment of
meeting space does not imply product endorsement nor
does the Oncology Nursing Society assume any
responsibility for the educational content.
|
Registration Information
There is no fee for attending this
symposium
GENERAL INFORMATION
Phone: 610-834-1810
REGISTRATION OPTIONS
Fax: Fill out and fax
this registration
card to 610-834-8856
Phone: 888-622-9927
Internet:
Click here
If registration is completed online, you will receive an
automatic confirmation.
Space is limited; seating will be on a first-come,
first-served basis. You are not guaranteed a seat upon
registration—arrive early for optimal seating.
Educational Grant
Nurses who attend this
activity and complete an evaluation form will be
eligible for a $500 educational grant to attend an
educational meeting of their choice. A random drawing
will be conducted immediately following the symposium.
MEI recognizes the importance of the Americans with
Disabilities Act (ADA). If you have special needs,
please contact us at least 3 weeks prior to this
activity, and we will make a reasonable effort to
accommodate your needs.
|
|
|